Molecularly Guided Combined Lutetium-177 FAP-2286 and DOTA-Ibandronic Therapy for Bone Metastases: A Dual-Tracer PET/CT Study (EANM 2026) - Sep 29, 2026 - Abstract #EP-0997; "Dual-tracer PET/CT revealed marked molecular heterogeneity in bone metastases. Combined lutetium-177 FAP-2286 and DOTA-ibandronic therapy was feasible, well tolerated, and associated with clinically meaningful pain relief and favourable early imaging response."
Solid Tumor
|